FDA Approval of LiquiBand® Rapid(TM)

RNS Number : 5215F
Advanced Medical Solutions Grp PLC
10 March 2020

10 March 2020


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


FDA Approval of LiquiBand® Rapid™



Winsford, UK – 10 March 2020: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces that it has received 510(k) approval from the US FDA (“Food and Drug Administration”) for the Group’s LiquiBand® Rapid™ product.


The product will be commercialised immediately via one of AMS’s main US partners and will upgrade this partner’s offering. The Group expects LiquiBand® Rapid™ to enable AMS to regain ground with an improved product. LiquiBand® Rapid™ is a further portfolio extension of AMS’s LiquiBand range, with a faster drying time than comparative products and multiple uses in operating room and emergency room settings.


Chris Meredith, Chief Executive Officer of AMS, commented: “The approval of LiquiBand® Rapid™ is an important development for our LiquiBand product range. Innovation remains a key driver of organic growth for the Group and this approval demonstrates the capabilities of our internal R&D and regulatory teams. The Group remains confident of the growth potential for the LiquiBand® range alongside multiple other woundcare and surgical opportunities including those arising from the acquisitions of Biomatlante and Sealantis.”



– End –


For further information, please visit www.admedsol.com or contact:


Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence



About Advanced Medical Solutions Group plc – see www.admedsol.com 


AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.


AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.